Aurealis Therapeutics announces approval of multi-center, randomized, placebo-controlled diabetic foot ulcer Phase 2 study to start May 2023 in Italy, Germany and Poland.
Aurealis Therapeutics, a Swiss-Finnish private clinical-stage synthetic biology company focusing on the development of lactic acid bacteria -based GMO cell and gene therapies, announces clinical trial application (CTA) approval of a multi-center, randomized, placebo-controlled diabetic foot ulcer (DFU) Phase 2 study to start this month in Italy, Germany, and Poland. The Global Coordinating Investigator of […]
Aurealis Therapeutics completes Phase 1 Last Patient Last Visit: After 12 months follow-up, no healed ulcer has recurred
Aurealis Therapeutics Phase 1 clinical study for non-healing Diabetic Foot Ulcers (DFUs) had its last patient last visit on March 20, 2023. We are incredibly happy to share while 83% of the patients receiving the lead therapeutic dose achieved complete healing, no healed ulcer has recurred after 12 months follow-up. This was the first clinical […]
Aurealis Therapeutics successfully completes treatment period of its Phase 1 study for AUP-16 in non-healing Diabetic Foot Ulcers: 83% patients receiving lead therapeutic dose achieved complete healing
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today that it has successfully completed its Phase 1 study of its lead therapeutic candidate AUP-16 in non-healing Diabetic Foot Ulcers patients, both in terms of patient recruitment and treatment. While patient observation period continues, collected data will be processed and […]
Aurealis Therapeutics Diabetic Foot Ulcer Dose Escalation Patient Trial Low Therapeutic Dose Cohort Completed Successfully, Advances to Medium Therapeutic Dose Group
Aurealis Therapeutics, a biopharmaceutical company developing its groundbreaking four-in-one technology -based product AUP-16, announced today that it has successfully completed the low therapeutic dose cohort in the diabetic foot ulcer (DFU) patient trial and has already enrolled and dosed the first patients in the medium therapeutic dose cohort. The primary endpoint of this dose escalation […]
Aurealis Therapeutics developing a drug therapy with multiple active substances in one product has initiated repeated dosing groups in the diabetic foot ulcer patient trial
Aurealis Therapeutics, a private clinical-stage biopharmaceutical company, is making a difference in chronic, non-healing wounds by developing a therapy with multiple active substances in one product that are hitting all key pathomechanisms. Chronic wound care needs curative drugs with true active pharmaceutical substances, not just incrementally improved dressings and devices. The company announced today that […]
Aurealis Therapeutics pioneering multiple drug producing bacteria AUP-16 dosed to the first diabetic foot ulcer patient in the Phase 1-2A trial
Aurealis Therapeutics, a private clinical-stage biopharmaceutical company developing AUP-16, the three-in-one combination biologic drug for chronic non-healing wounds and regenerative diseases, announced today that the first diabetic foot ulcer (DFU) patient has been dosed with AUP-16. The trial is performed in non-healing DFU patients and is designed to evaluate the safety, tolerability and preliminary efficacy […]
Aurealis Therapeutics receives clinical trial application approval for the AUP-16 Phase 1 clinical study in DFU patients
Aurealis Therapeutics, a private biopharmaceutical company developing AUP-16, the three-in-one combination biologic drug for chronic non-healing wounds and regenerative diseases, announced today clinical trial application (CTA) approval of the AUP-16 phase 1 diabetic foot ulcer (DFU) patient trial by the German Health Authority Paul-Ehrlich-Institute. The company plans to enroll the first patient to the phase […]